Home › Funds › AMF Tjanstepension AB › VRTX

AMF Tjanstepension AB position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

AMF Tjanstepension AB reported holding 388,770 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$203.3M, representing 1.18% of its reported portfolio and ranking #25 among its reported holdings. AMF Tjanstepension AB has disclosed VRTX holdings in 11 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)388.77K sh
Reported value held$203.25M
Portfolio Weight1.18%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How AMF Tjanstepension AB's VRTX position evolved

AMF Tjanstepension AB first disclosed a stake in VRTX in Q3 2023 at 18,890 shares (US$6.6M). The position peaked in Q2 2024 at 549,700 shares, worth US$257.7M. Across 11 filings, AMF Tjanstepension AB increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 388,770 shares valued at US$203.3M — an increase of 74,005 shares quarter over quarter.. Notable position changes include a 69% trim in Q3 2024 (shares fell 13% over the following quarter), a 134% increase in Q4 2025 (shares fell 1% over the following quarter), a 114% increase in Q1 2026 (shares rose 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 18.89K $6.57M New
Q2 2024 549.70K $257.66M New
Q3 2024 167.92K $78.10M Reduce
Q4 2024 67.76K $27.29M Reduce
Q1 2025 60.99K $29.57M Reduce
Q2 2025 64.70K $28.81M Add
Q3 2025 62.46K $24.46M Reduce
Q4 2025 145.95K $66.17M Add
Q1 2026 312.92K $139.73M Add
Q2 2026 314.76K $156.35M Add
Q3 2026 388.77K $203.25M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has AMF Tjanstepension AB held VRTX?

AMF Tjanstepension AB has disclosed VRTX holdings in 11 of the last 13 reported quarters, going back to Q3 2023.

What is AMF Tjanstepension AB's current position in VRTX?

As of Q3 2026, AMF Tjanstepension AB holds 388.77K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $203.25M, representing 1.18% of its reported portfolio and ranking #25.

Has AMF Tjanstepension AB been buying or selling VRTX?

In the latest 13F filing (Q3 2026), AMF Tjanstepension AB increased its position in VRTX. The position peaked in Q2 2024 at 549.70K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.